Dr Hasit Joshipuria, MD, GSK
The vaccines sales of GlaxoSmithKline in 2013-14 recorded a 12 percent growth over the previous year's figures. The company recorded Rs 361.9 crore as revenue in FY 2013-14 as compared to Rs 312 crore in the previous fiscal year.
In the area of preventive healthcare, GSK Vaccines became the leading company in the private market for vaccines in India. The recently introduced vaccine for pneumococcal conjugate disease, Synflorix, became the biggest brand in the vaccine portfolio of the company in the second year of its launch. The efforts of GSK in raising awareness about vaccines against preventable diseases continued with increasing fervor.
Exports recorded a sales turnover of Rs 9.5 crore comprising of both Bulk Drugs and
Formulations. Exports of Bulk Drugs were to major markets like Japan, France, Jordan, and Sri Lanka.
Some of the innovator products approved by the regulatory agency in India during the year under review, include a biological oncology product Panitumumab, in-licensed from Amgen (Vectibix) for the treatment of patients of metastatic colorectal carcinoma as a third line treatment option, a line extension for amoxicillin and clavulanic acid formulation (Augmentin Drops) for paediatric use, expansion of use of DTaP vaccine (Boostrix) for use in adults and new indication for the use of cefixime formulation (Cefspan) in enteric fever. All these new products approved for the company during the year under review will be beneficial to Indian patients.
In addition, the company also received approval for import and marketing of seven cosmetic products in India. GSK globally continues to be committed to research and development of medicines that will improve the quality of life of people around the world and truly make a difference to patients.
GSK PLC, the parent organization of the company, is one of the biggest investors in R&D to bring new products and vaccines to the market.